ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity

ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity Salt Lake City, UT, October 3, 2019 – ProLung, Inc. (“ProLung” or the “Company”) and its long-time partner ProLung China (a Delaware, USA-based company), both whom are focused on reducing the time to diagnosis for lung cancer patients, proudly announced today [...]

ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity2019-10-16T16:35:55-06:00

ProLung Announces the Appointment of Leavitt Partners and Mr. Rich McKeown to its Board of Directors

Salt Lake City, UT, August 12, 2019 – ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients, announced today the appointment of Leavitt Partners to the ProLung Board of Directors with Mr. Rich McKeown acting as its designee. The appointment of Leavitt Partners, and Mr. [...]

ProLung Announces the Appointment of Leavitt Partners and Mr. Rich McKeown to its Board of Directors2019-09-08T23:13:09-06:00

ProLung interim CEO, Jared Bauer, is a “Top Creative Leader Innovating in Business 2019” by Insights Success Magazine – ProLung, Inc.

ProLung is proud to share that our interim CEO, Jared Bauer, has been highlighted as a "Top Creative Leader Innovating in Business 2019" by Insights Success Magazine. Follow the link to learn more about Jared's personal history, passion for the medtech industry, professional accomplishments and non-profit organization that he started with his wife. Jared Bauer [...]

ProLung interim CEO, Jared Bauer, is a “Top Creative Leader Innovating in Business 2019” by Insights Success Magazine – ProLung, Inc.2019-07-19T00:00:00-06:00

ProLung Announces Changes to its Board of Directors and Leadership Team to Enhance its Medtech Expertise – ProLung, Inc.

1012Salt Lake City, UT, June 12, 2019 – ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients, announced the appointments of Messers. Jim Hogan, David Nielsen and Don Patterson to enhance the medtech expertise and general management leadership on the Board, while J. Scott Nixon [...]

ProLung Announces Changes to its Board of Directors and Leadership Team to Enhance its Medtech Expertise – ProLung, Inc.2019-06-12T00:00:00-06:00

ProLung Announces New Office Location as Anchor Tenant at 'The Labs at Northgate' – ProLung, Inc.

SALT LAKE CITY, UT / ACCESSWIRE / June 10, 2019 / ProLung, Inc. ("ProLung" or the "Company"), which is focused on reducing the time to diagnosis for lung cancer patients, announced today it has started construction on a new office and laboratory location at 'The Labs at Northgate' in Salt Lake City, Utah. The new [...]

ProLung Announces New Office Location as Anchor Tenant at 'The Labs at Northgate' – ProLung, Inc.2019-06-10T00:00:00-06:00

ProLung named Med Tech Company of the Year 2019 by Global Health & Pharma – ProLung, Inc.

ProLung is delighted to be honored as the “Med Tech Company of the Year 2019” by Global Health & Pharma. Our ProLung team views external recognition as further validation of our mission to ‘make a difference in time’ for lung cancer patients who face under-prioritized and highly stigmatized disease that is still the leading cause [...]

ProLung named Med Tech Company of the Year 2019 by Global Health & Pharma – ProLung, Inc.2019-03-08T00:00:00-06:00

ProLung Announces Preliminary Results from its PL-208 Clinical Trial and Next-Steps – ProLung, Inc.

Salt Lake City, UT, February 1, 2019 – ProLung, Inc. (“ProLung” or the “Company”), which is focused on reducing the time to diagnosis for lung cancer patients with its ProLung Test™, yesterday announced the preliminary results of its PL-208 Validation Study and outlined its next-steps during a Shareholder Update teleconference call. Before breaking the Study [...]

ProLung Announces Preliminary Results from its PL-208 Clinical Trial and Next-Steps – ProLung, Inc.2019-02-01T00:00:00-06:00

ProLung named one of 50 Leading Companies of the Year 2018 by Silicon Review – ProLung, Inc.

ProLung, Inc. is honored to be named one of the ‘50 leading companies of the year 2018’ by Silicon Review. Furthermore, our interim CEO, Mr. Jared Bauer, is interviewed in their end of the year special issue where he discusses how ProLung is focused on ‘making a difference in time’ for lung cancer patients. Read [...]

ProLung named one of 50 Leading Companies of the Year 2018 by Silicon Review – ProLung, Inc.2018-12-18T00:00:00-06:00

ProLung Announces Voting Results from its 2018 Annual Meeting of Shareholders – ProLung, Inc.

SALT LAKE CITY, UT / ACCESSWIRE / December 13, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') is focused on reducing the time to diagnosis for lung cancer patients. ProLung® conducted its 2018 Annual Meeting of Shareholders (''Meeting'') last week with support from many of the individuals who participated in the recent Consent Solicitation, which [...]

ProLung Announces Voting Results from its 2018 Annual Meeting of Shareholders – ProLung, Inc.2018-12-13T00:00:00-06:00

ProLung Announces Final Results from its PL-209 Repeatability Study – ProLung, Inc.

SALT LAKE CITY, UT / ACCESSWIRE / November 21, 2018 / ProLung, Inc. ("ProLung" or the "Company") is focused on reducing the time to diagnosis for lung cancer patients. Today ProLung announced final results from its PL-209 repeatability study. The ProLung Test is designed to produce a personalized risk score indicating the likelihood of malignancy [...]

ProLung Announces Final Results from its PL-209 Repeatability Study – ProLung, Inc.2018-11-21T00:00:00-06:00